# OnCo record nct04214288 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04214288/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04214288", "NCT04214288" ;
  schema:name "A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer"@en ;
  schema:alternateName "SERENA-2"@en ;
  schema:description "A phase 2 trial of Camizestrant and Fulvestrant in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04214288/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04214288> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2020-04-22" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/drugs/fulvestrant/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04214288-lancet-oncol-2024/> .